These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
390 related articles for article (PubMed ID: 26881714)
21. Comparative analysis of small molecules and histone substrate analogues as LSD1 lysine demethylase inhibitors. Culhane JC; Wang D; Yen PM; Cole PA J Am Chem Soc; 2010 Mar; 132(9):3164-76. PubMed ID: 20148560 [TBL] [Abstract][Full Text] [Related]
22. QSAR Modeling, Molecular Docking and Molecular Dynamics Simulations Studies of Lysine-Specific Demethylase 1 (LSD1) Inhibitors as Anticancer Agents. Abdizadeh R; Heidarian E; Hadizadeh F; Abdizadeh T Anticancer Agents Med Chem; 2021; 21(8):987-1018. PubMed ID: 32698753 [TBL] [Abstract][Full Text] [Related]
23. Enantioselective synthesis of tranylcypromine analogues as lysine demethylase (LSD1) inhibitors. Benelkebir H; Hodgkinson C; Duriez PJ; Hayden AL; Bulleid RA; Crabb SJ; Packham G; Ganesan A Bioorg Med Chem; 2011 Jun; 19(12):3709-16. PubMed ID: 21382717 [TBL] [Abstract][Full Text] [Related]
25. Lysine-specific demethylase 1-mediated demethylation of histone H3 lysine 9 contributes to interleukin 1β-induced microsomal prostaglandin E synthase 1 expression in human osteoarthritic chondrocytes. El Mansouri FE; Nebbaki SS; Kapoor M; Afif H; Martel-Pelletier J; Pelletier JP; Benderdour M; Fahmi H Arthritis Res Ther; 2014 May; 16(3):R113. PubMed ID: 24886859 [TBL] [Abstract][Full Text] [Related]
26. Design, synthesis and in vitro/in vivo anticancer activity of tranylcypromine-based triazolopyrimidine analogs as novel LSD1 inhibitors. Li Z; Yuan Y; Wang P; Zhang Z; Ma H; Sun Y; Zhang X; Li X; Qiao Y; Zhang F; Su Y; Song J; Xie Z; Li L; Ma L; Ma J; Zhang Z Eur J Med Chem; 2023 May; 253():115321. PubMed ID: 37037137 [TBL] [Abstract][Full Text] [Related]
27. Towards the development of activity-based probes for detection of lysine-specific demethylase-1 activity. Ourailidou ME; Lenoci A; Zwergel C; Rotili D; Mai A; Dekker FJ Bioorg Med Chem; 2017 Feb; 25(3):847-856. PubMed ID: 27989416 [TBL] [Abstract][Full Text] [Related]
28. Crystal structure of histone demethylase LSD1 and tranylcypromine at 2.25 A. Mimasu S; Sengoku T; Fukuzawa S; Umehara T; Yokoyama S Biochem Biophys Res Commun; 2008 Feb; 366(1):15-22. PubMed ID: 18039463 [TBL] [Abstract][Full Text] [Related]
29. Tranylcypromine and 6-trifluoroethyl thienopyrimidine hybrid as LSD1 inhibitor. Wang X; Su M; Li Y; Liu T; Wang Y; Chen Y; Tang L; He YP; Ding X; Yu F; Shen J; Li J; Zhou Y; Chen YL; Xiong B Bioorg Med Chem Lett; 2019 Mar; 29(6):844-847. PubMed ID: 30713023 [TBL] [Abstract][Full Text] [Related]
30. Synthesis of Carboxamide-Containing Tranylcypromine Analogues as LSD1 (KDM1A) Inhibitors Targeting Acute Myeloid Leukemia. Teresa Borrello M; Benelkebir H; Lee A; Hin Tam C; Shafat M; Rushworth SA; Bowles KM; Douglas L; Duriez PJ; Bailey S; Crabb SJ; Packham G; Ganesan A ChemMedChem; 2021 Apr; 16(8):1316-1324. PubMed ID: 33533576 [TBL] [Abstract][Full Text] [Related]
31. Development and Structural Evaluation of N-Alkylated trans-2-Phenylcyclopropylamine-Based LSD1 Inhibitors. Niwa H; Sato S; Handa N; Sengoku T; Umehara T; Yokoyama S ChemMedChem; 2020 May; 15(9):787-793. PubMed ID: 32166890 [TBL] [Abstract][Full Text] [Related]
32. Heterocycle-containing tranylcypromine derivatives endowed with high anti-LSD1 activity. Fioravanti R; Rodriguez V; Caroli J; Chianese U; Benedetti R; Di Bello E; Noce B; Zwergel C; Corinti D; Viña D; Altucci L; Mattevi A; Valente S; Mai A J Enzyme Inhib Med Chem; 2022 Dec; 37(1):973-985. PubMed ID: 35317680 [TBL] [Abstract][Full Text] [Related]
33. Targeting Histone Lysine Demethylase LSD1/KDM1A as a New Avenue for Cancer Therapy. Fang Y; Liao G; Yu B Curr Top Med Chem; 2019; 19(11):889-891. PubMed ID: 31389779 [No Abstract] [Full Text] [Related]
34. Structural basis for the inhibition of the LSD1 histone demethylase by the antidepressant trans-2-phenylcyclopropylamine. Yang M; Culhane JC; Szewczuk LM; Jalili P; Ball HL; Machius M; Cole PA; Yu H Biochemistry; 2007 Jul; 46(27):8058-65. PubMed ID: 17569509 [TBL] [Abstract][Full Text] [Related]
36. Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia. Feng Z; Yao Y; Zhou C; Chen F; Wu F; Wei L; Liu W; Dong S; Redell M; Mo Q; Song Y J Hematol Oncol; 2016 Mar; 9():24. PubMed ID: 26970896 [TBL] [Abstract][Full Text] [Related]
37. Targeting LSD1 for acute myeloid leukemia (AML) treatment. Zhang S; Liu M; Yao Y; Yu B; Liu H Pharmacol Res; 2021 Feb; 164():105335. PubMed ID: 33285227 [TBL] [Abstract][Full Text] [Related]
38. Lysine-specific demethylase 1-selective inactivators: protein-targeted drug delivery mechanism. Ogasawara D; Itoh Y; Tsumoto H; Kakizawa T; Mino K; Fukuhara K; Nakagawa H; Hasegawa M; Sasaki R; Mizukami T; Miyata N; Suzuki T Angew Chem Int Ed Engl; 2013 Aug; 52(33):8620-4. PubMed ID: 23824985 [No Abstract] [Full Text] [Related]
39. Reversible Lysine Specific Demethylase 1 (LSD1) Inhibitors: A Promising Wrench to Impair LSD1. Dai XJ; Liu Y; Xue LP; Xiong XP; Zhou Y; Zheng YC; Liu HM J Med Chem; 2021 Mar; 64(5):2466-2488. PubMed ID: 33619958 [TBL] [Abstract][Full Text] [Related]
40. Discovery of tranylcypromine analogs with an acylhydrazone substituent as LSD1 inactivators: Design, synthesis and their biological evaluation. Sun K; Peng JD; Suo FZ; Zhang T; Fu YD; Zheng YC; Liu HM Bioorg Med Chem Lett; 2017 Nov; 27(22):5036-5039. PubMed ID: 29037950 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]